Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 2, 2013, Pages 214-220

  Oran, Betul ^a   Popat, Uday ^a   Rondon, Gabriella ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   Abruzzo, Lynn ^a   Andersson, Borje S ^a   Bashir, Qaiser ^a   Chen, Julianne ^a   Kebriaei, Partow ^a   Khouri, Issa F ^a   Koca, Ebru ^a   Qazilbash, Muzaffar H ^a   Champlin, Richard ^a   De Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; AML; Minimal residual disease

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PENTOSTATIN; SORAFENIB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; UNRELATED DONORS;

ADULT; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872606296     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.09.002     Document Type: Article

References (26)

1. Oran B., Weisdorf D.J. Allogeneic stem cell transplantation in first complete remission. Curr Opin Hematol 2011, 18:395-400.
2. Hokland P., Ommen H.B. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011, 117:2577-2584.
3. Maurillo L., Buccisano F., Del Principe M.I., et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008, 26:4944-4951.
4. Lodewyck T., Cornelissen J.J. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. Blood Rev 2008, 22:293-302.
5. Pavletic S.Z., Kumar S., Mohty M., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:871-890.
6. Elorza I., Palacio C., Dapena J.L., et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010, 95:936-941.
7. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998, 92:4072-4079.
8. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011, 29:1190-1197.
9. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
10. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine +/- fludarabine with once-daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
11. Parmar S., Andersson B.S., Couriel D., et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol 2011, 29:294-302.
12. Oran B., de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 2011, 18:388-394.
13. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
14. Cox D.R. Regression models and life tables. J Royal Stat Soc B 1972, 34:187-220.
15. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
16. Chen Y., Cortes J., Estrov Z., et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem cell transplantation. J Clin Oncol 2011, 29:2507-2513.
17. Kronke J., Schlenk R.F., Jensen K.O., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011, 29:2709-2716.
18. Freireich E.J., Cork A., Stass S.A., et al. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 1992, 6:500-506.
19. Marcucci G., Mrozek K., Ruppert A.S., et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol 2004, 22:2410-2418.
20. Grimwade D., Walker H., Oliver F., et al. Medical Research Council Leukaemia Working Parties. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Bone Marrow Transplant 1997, 19:1117-1123.
21. Tallman M.S., Rowlings P.A., Milone G., et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000, 96:1254-1258.
22. Cahn J.Y., Labopin M., Sierra J., et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Br J Haematol 2000, 110:308-314.
23. Sproat L., Bolwell B., Rybicki L., et al. Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission. Leuk Lymphoma 2010, 51:1699-1704.
24. Buccisano F., Maurillo L., Del Principe M.I., et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012, 119:332-341.
25. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
26. Pagel J.M., Appelbaum F.R., Eary J.F., et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107:2184-2191.